35
Views
22
CrossRef citations to date
0
Altmetric
Original Articles

Treatment of Heterotopic Ossification After Spinal Cord Injury

, M.D., , P.A. & , M.D.
Pages 60-65 | Received 15 Jul 1996, Accepted 26 Aug 1996, Published online: 11 May 2016

REFERENCES

  • Abrasion AS. Bone disturbances in injuries to spinal cord and cauda equina (paraplegia): their prevention by ambulation. J Bone Joint Surg 1947;30:982-91.
  • Heilburn N, Kuhn WG Jr. Erosive bone lesions and soft tissue ossifications associated with spinal cord injuries (paraplegia). Radiol 1947;48:579-85.
  • Liberson M. Soft tissue calcifications in cord lesions. JAMA 1953;152:1010-5.
  • Finerman GA, Stover SL. Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHPD. Metab Bone Dis Rel Res 1981;3:337-42.
  • Garland DE. A clinical perspective on common forms of acquired heterotopic ossification. Clin Ortho Rel Res 1991;263:13-29.
  • Ditunno JF Jr, Formal CS. Chronic spinal cord injury. New Engl J Med 1994;330:550-6.
  • Garland DE, Orwin JF. Resection of heterotopic ossification in patients with spinal cord injuries. Clin Ortho Rel Res 1989;242:169-76.
  • Puzas JE, Miller MD, Rosier RN. Pathologic bone formation. Clin Ortho Rel Res 1989;245:269-81.
  • Kurer MH, Khoker MA, Dandona P. Human osteoblast stimulation by sera from paraplegic patients with heterotopic ossification. Paraplegia 1992;30:165-8.
  • Renfree KJ, Banovac K, Hornicek FJ, Lebwohl NH, Villanueva PA, Nedd KJ. Evaluation of serum osteoblast mitogenic activity in spinal cord and head injury patients with acute heterotopic ossification. Spine 1994;19:740-6.
  • Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-44.
  • Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-4.
  • Freed JH, Hahn H, Menter R, Dillon T. The use of the three- phase bone scan in the early diagnosis of heterotopic ossification (HO) and in the evaluation of Didronel therapy. Paraplegia 1982;20:208-16.
  • American Spinal Injury Association. Standards for neurological and functional classification of spinal cord injury, 1992.
  • Banovac K, Gonzalez F, Wade N, Bowker J. Intravenous disodium etidronate therapy in spinal injury patients with heterotopic ossification. Paraplegia 1993;31:660-6.
  • Mysiw WJ, Tan J, Jackson RD. Heterotopic ossification. The utility of osteocalcin in diagnosis and management. Am J Phys Med Rehabil 1993;72:184-7.
  • Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med 1985;26:125–32.
  • Garland DE, Alday B, Venos KG. Heterotopic ossification and H LA antigens. Arch Phys Med Rehabil 1984;65:531-2.
  • Minaire P, Betuel H, Girard R, Pilonchery G. Neurologic injuries, paraosteoarthropathies, and human leukocyte antigens. Arch Phys Med Rehabil 1980;61:214-5.
  • Weiss S, Grosswasser Z, Ohri A, et al. Histocompatibility (HLA) antigens in heterotopic ossification associated with neurological injury. J Rheum 1979;6:88-91.
  • Bodley R, Jamous A, Short D. Ultrasound in the early diagnosis of heterotopic ossification in patients with spinal injuries. Paraplegia 1993;31:500-6.
  • Suzuki Y, Hisada K, Takeda M. Demonstration of myositis ossificans by 99mTc pyrophosphate bone scanning. Radiol 1974;111:663-4.
  • Stover SL, Hahn HR, Miller JM 3d. Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury (preliminary report). Paraplegia 1976;14:146-56.
  • Garland DE, Alday B, Venos KG, Vogt JC. Diphosphonate treatment for heterotopic ossification in spinal cord injury patients. Clin Ortho Rel Res 1983;176:197-200.
  • Garland DE. Clinical observations on fractures and heterotopic ossification in the spinal cord and traumatic brain injured populations. Clin Ortho Rel Res 1988;233:86-101.
  • Nakahara H, Yochikawa H, Takaoka K, Ono K. Effect of ethane-1-hydroxy-1,1-diphosphonate on ectopic bone formation induced by murine osteosarcoma-derived bone-inducing substance. Bone 1986;7:229-33.
  • Canfield RE. Etidronate disodium: a new therapy for hypercalcemia of malignancy. Am J Med 1987;82:1-78.
  • Kanis JA, Urwin GH, Gray, RE, et al. Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med 1987;82:55-70.
  • McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 1987;8:35-41.
  • Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 1982;72:221-6.
  • Recker RR, Saville PD. Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol Appl Pharmacol 1973;24:580-9.
  • Physician’s Desk Reference. 48th Ed. New Jersey; Medical Economics Data, 1994.
  • Khairi MR, Johnston CC. Treatment of Paget’s disease of bone (osteitis deformans) with sodium etidronate (AHDP). Clin Ortho Rel Res 1977;127:94-105.
  • Johnston CC Jr, Altman RD, Canfield RE, Finerman GA, Taulbee JD, Ebert ML. Review of fracture experience during treatment of Paget’s disease of bone with etidronate disodium (EHDP). Clin Ortho Rel Res 1983;172:186-94.
  • Kjaesgaard-Andersen P, Schmidt SA. Total hip arthroplasty. The role of anti-inflammatory medications in the prevention of heterotopic ossification. Clin Ortho Rel Res 1991;263:78-86.
  • Ayers DC, Pellegrini VD Jr, Evarts C. Prevention of heterotopic ossification in high-risk patients by radiation therapy. Clin Ortho Rel Res 1991;263:87-93.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.